Patient P-02462
Therapy response
Improving
Tolerance
Improving
GI state
Favorable
Inflammatory state
Improving
Nutritional resilience
Favorable
Discontinuation risk
18%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S12
- Day 30 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 55 DT-01 recommended — Dosing / Timing Recommendation DT-01
- Day 56 Patient accepted — Started DT-01 in the companion
- Day 61 GI symptom burden −18% vs expected — Dosing / Timing Recommendation DT-01
- Day 67 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 30.
Primary contributors, last 14 days
- Toxicity-7
- Inflammatory activity-5
- GI instability+3
- Treatment adherence+2
What helped?
- Dosing / Timing Recommendation DT-01Day 55Result: symptom burden −18%
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients.
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Inflammatory signalling ↓45
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- Mucosal barrier integrity ↓30
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Butyrate / short-chain fatty acid production ↓25
- MicrobiomeF. prausnitzii depleted
- Autonomic recovery ↓20
- WearableShort sleep window
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
- GLP1R rs6923761 AAltered receptor sensitivity
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 4.1 · butyrate capacity 63/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 51 ms
- Sleep
- 6.5 h
- Steps
- 8,357
- Resting HR
- 64 bpm
Daily log: GI score 22, nutritional resilience 63, adherence 98.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.